Osimertinib-associated cardiac dysfunction in epidermal growth factor receptor-mutant non-small cell lung cancer: a single-center three-case series requiring hospitalization

Background: Osimertinib is frequently used for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), whereas cardiotoxicity signals, including left ventricular ejection fraction (LVEF) decline, heart failure (HF), and corrected QT interval prolongation, have been documen...

詳細記述

書誌詳細

主要な著者:	Masao Takemura, Shun Inoue, Akari Neoi, Daisuke Yoshida, Nao Shibata, Kentaro Hara, Takami Kobayashi, Ikuo Wakamatsu, Kohei Taguchi, Kazue Umetsu, Shunichi Kouno, Kana Ikeda, Mitsuru Motegi
フォーマット:	Artigo
言語:	Inglês
出版事項:	Elsevier 2026-01-01
シリーズ:	Respiratory Medicine Case Reports
主題:	NSCLC EGFR mutation Osimertinib Drug-induced cardiotoxicity Heart failure Left ventricular ejection fraction
オンライン･アクセス:	http://www.sciencedirect.com/science/article/pii/S2213007126000596
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!